Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 30, 2024, titled "Zydus Lifesciences launches Rexigo , the oral once-a-day pill for advanced prostate cancer patients in India".
Press Release Jan 30 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the launch of Rexigo™, an oral once-a-day pill for advanced prostate cancer patients in India. This therapy, which suppresses testosterone, is the first of its kind available in India, providing a more convenient alternative to injectable treatments. The launch aims to improve access and affordability for patients, as Rexigo™ is priced significantly lower than existing options.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 25 2024
- Press Release Jan 19 2024
- Press Release Jan 17 2024
- Press Release Dec 22 2023
- Press Release Dec 16 2023
Later from Zydus Lifesciences
- Press Release Feb 08 2024
- Press Release Feb 09 2024
- Press Release Feb 16 2024
- Zydus Lifesciences Limited Press Release Feb 26 2024
- Press Release Mar 13 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences